ARQT
Arcutis Biotherapeutics Inc
Sign up for free!
Get instant access to stock market data and news with our free APIs.
Real-time data
- Listing exchange
- NASDAQ Stock Exchange
- Price
- $16.72
- Day High
- $16.89
- Day Low
- $16.39
- Day Open
- $16.39
- Volume
- 19644
- Day Change
- 1.14%
Latest news data for ARQT
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
globenewswire.com
Roivant Sciences: Good Prospects For 2023 (NASDAQ:ROIV)
seekingalpha.com
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
globenewswire.com
ARQT stock on hold as Phase 3 trial for atopic dermatitis therapy succeeds (NASDAQ:ARQT)
seekingalpha.com
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis
prnewswire.com
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
globenewswire.com
ARQT stock gains as late-stage atopic dermatitis trial meets key goals (NASDAQ:ARQT)
seekingalpha.com
Arcutis Biotherapeutics' dermatitis cream meets main goal of late-stage trial
marketscreener.com
Arcutis Biotherapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:ARQT)
seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Call Transcript
seekingalpha.com